u/mod_cold_room

The source pages link the supplier’s own storefront on purpose, so you can read their account against ours.

Four observations is not a distribution. The lane tables here only became predictive once individual routes had a dozen or more reports behind them.

Bought small, tested identity first, and only then thought about anything else. That order felt right.

Total transit decomposes into first mile, international leg, clearance and last mile. Only the first two are meaningfully under the shipper’s control and most reported variance sits in the last two.

insulation buys hours, not days

Asked QST which lines they hold regionally before ordering and got a straight list back. Changed what I ordered and when.

A quoted lead time is a commitment you can evaluate.

This is why the lane table is organised the way it is. The supplier is not the unit.

Clearance took three days and the carrier took nine. I had been blaming the wrong half for two years.

Agreed. The hepatic programme is the point of this compound and the weight discussion is a side effect of the side effect.

Is the goal weight still the one you picked at the start?

the TGA shortage database is public and it is the source, not the news

the interesting column is spread, not maximum

That reads as a titration plan for an unapproved compound. This board cannot host that and it should not want to.

Did the pharmacy check with the wholesaler, or is that a shelf observation?

What maintenance actually looks like, from the people on this board who have been in it longest.

You find a dose or an interval that holds the weight with side effects you barely notice, and then you stop optimising. Weigh monthly rather than daily. Expect a couple of kilos of range and do not act on it. Keep the habits that did the work in the losing phase, because they are the part that has to outlive the dose.

The most common mistake described here is treating arrival as a plateau and pushing the dose to chase a number chosen at week one by a person who did not yet know what maintenance felt like.

Maintenance posts are the most underrated content here and they get a fraction of the votes.

Why identity, not purity, is the test to buy here.

This is a short peptide with a published sequence. Synthesis is not difficult, which means the market is wide and the analytical question shifts. A high area-percent figure tells you the sample is homogeneous; it does not tell you the homogeneous material is the sequence you ordered.

Mass spectrometry, with the theoretical mass alongside the measured one, converts a purity claim into an identity claim. It costs a little more and it answers the question that actually matters. Ask for it, and ask suppliers whether they can provide it before you order — the answers are informative in themselves.

reship policy in writing before the order, not after

That is a lane problem rather than a packaging problem, and the fixes are different.

Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.

Left up and added to the lane table. Origin, destination and month were all included, which is all we ask.

Switching from semaglutide, since three people asked in this thread alone.

There is no published dose equivalence between the two. The conversion tables that circulate are somebody’s arithmetic, not data. What people report here is that the first month after a switch is often flat, that the appetite effect feels differently shaped rather than simply stronger, and that starting at the bottom of the ladder again is the common approach.

None of that is a recommendation. It is what the threads say, and the threads are not a clinic.

Cosigning the regional stock point.

kofi_ferreira is right that the pack failing is not the material failing. Two separate claims.

Correction to my own post above — I said 10mg and I have been on 2.5mg since the spring. Same argument, wrong number.

Left up and added to the lane table. Origin, destination and month were all included, which is all we ask.

glucagon agonism and energy expenditure is the mechanistic thread

Agreed — and the endpoint definitions are where the actual claim lives.

this board is small because the compound is early

Retitled: the original asserted degradation the post does not evidence.

regulatory status varies by jurisdiction and it has moved recently

Agreed, and the glucagon arm is exactly why the comparison threads do not work.

Adding the standing caveat: none of this is approved anywhere and research material is not for human use.

Appetite effect for me is flat across seven days. On sema it was a wave. Same person, different molecule.

What is the plan if the drift continues for another month?

That figure is from the obesity programme, and this thread is about the hepatic one.

Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use.

It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.

Where in the fridge is it sitting now?

declared value and description are the shipper’s decision, ask what they use

What lead time were you quoted at checkout?

the glucagon component is why the metabolic story reads differently